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PURPOSE. -Toxin mediates extreme corneal damage during
Staphylococcus aureus keratitis. Chemical inhibition of this
toxin was sought to provide relief from toxin-mediated pathol-
ogy.
METHODS. Inhibition of -toxin by phosphate-buffered saline
(PBS), 0.1% methyl--cyclodextrin (CD), or CD plus choles-
terol (0.1%, CD-cholesterol) was assayed by hemolysis of
rabbit erythrocytes. Pathologic changes in rabbit corneas
injected with 12 hemolytic units of -toxin suspended in
PBS, 1% CD, or 1% CD-cholesterol were compared over time.
Rabbit corneas injected with 102 colony forming units (CFU)
of S. aureus were treated from 7 to 13 hours postinfection
(PI) with a total of 15 drops of CD-cholesterol, CD, or PBS.
Slit lamp examination (SLE) and measurement of erosions
were performed at 13 hours PI and bacteria were quantified
at 14 hours PI.
RESULTS. Toxin-mediated lysis of erythrocytes was inhibited up
to 16,000-fold in the presence of CD-cholesterol compared
with CD or PBS. Eyes injected with -toxin mixed with CD-
cholesterol had, at 7 hours postinjection, significantly smaller
erosions than eyes injected with -toxin in PBS or -toxin
mixed with CD (P  0.0090 and P  0.0035, respectively).
Eyes infected with S. aureus and treated with CD-cholesterol
had significantly lower SLE scores than eyes treated with CD or
PBS (P  0.0103 and P  0.0017, respectively); however, there
were no differences in the number of bacteria present (P 
0.0648).
CONCLUSIONS. CD-cholesterol is a potent inhibitor of -toxin
activity in vitro and an effective means to arrest corneal dam-
age during S. aureus keratitis. (Invest Ophthalmol Vis Sci.
2009;50:2848–2854) DOI:10.1167/iovs.08-3157
Agram-positive coccus, Staphylococcus aureus, is one ofthe most important human pathogens. S. aureus causes a
variety of infections with high morbidity and mortality includ-
ing osteomyelitis, soft tissue infections, pneumonia, endocar-
ditis, and brain abscesses.1–4 In the United States, there are
approximately 292,000 hospital admissions of S. aureus infec-
tion annually.5 A survey showed that 19,000 people died in
2006 from S. aureus infections.6 To further intensify the scope
of the problem, the rate of methicillin-resistant S. aureus iso-
lates found both in the community and in hospitals is continu-
ing to increase.5,7–9
S. aureus is also a major cause of ocular infections, includ-
ing blepharitis, conjunctivitis, keratitis, and endophthalmi-
tis.10–12 Patients with these infections have intense pain, red-
ness, and photophobia, and the infection can result in an ulcer
with numerous infiltrating polymorphonuclear leukocytes.10
These infections can result in loss of visual acuity or blindness.
Intensive antibiotic therapy can eradicate S. aureus from the
infected site, but pathologic changes can continue due to
action of toxic proteins that are secreted by S. aureus.13 The
appearance of an infected eye may not be a good measure of
the success of antibiotic treatment because the activity of the
secreted toxins is not directly affected by the antibiotic-medi-
ated killing of the bacteria.
An extremely important S. aureus protein that mediates
ocular tissue damage is -toxin.14 –16 -Toxin has also been
proven to have an important role in brain and respiratory
infections caused by S. aureus and is being proposed as a
vaccine target for humans.17–20 -Toxin is a 33 kDa protein
that forms a ring of seven -toxin molecules that penetrate
the host cell membrane forming a pore, causing cell lysis.21
-Toxin has also been demonstrated to cause cellular
changes in human cells, upregulate inflammatory cytokines,
cause calcium disruptions reducing host defenses, and cause
apoptosis.22–27 Furthermore, -toxin has been shown to be
an important virulence factor in both rabbit and murine
models of keratitis.15,16,28,29 When the -toxin gene was
mutated, the pathology associated with the infection was
significantly reduced compared to the parent strain.15 How-
ever, when the mutated -toxin gene in the knockout strain
was complemented, the pathology was restored.15
To date, there are no known inhibitors of -toxin avail-
able to treat S. aureus infection, including ocular infections.
There have been efforts to develop inhibitors of this impor-
tant virulence factor including the use of steroids or steroid-
like molecules.30,31 Pany et al.32 demonstrated that -toxin
binds to caveolin, a protein present in lipid rafts. -Toxin
has a caveolin-1 binding motif that, when removed, results
in a nonhemolytic form of -toxin.32 Peptides that mimic the
caveolin-binding domain of -toxin have been shown to
limit the action of -toxin on cell membranes.33 Gu et al.34
showed that methyl--cyclodextrin (CD) can bind weakly to
the pore of -toxin heptamer. On introducing amino acid
changes in the -toxin, Gu et al.34 were able to increase the
binding of CD. Furthermore, Vijayvargia et al.35 observed
that cholesterol depletion of cells arrested the action of
-toxin and that chelation of cholesterol, using CD, helped
retard the pore formation by -toxin. Karginov et al.36 have
demonstrated that -toxin action can be inhibited by posi-
tively charged side groups chemically attached to CD.
The studies presented herein test the hypothesis that a
complex of cholesterol and CD (CD-cholesterol) can inhibit
the action of -toxin. The results show that CD-cholesterol
complex can inhibit -toxin action in vitro and in vivo.
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MATERIALS AND METHODS
Bacteria
Staphylococcus aureus strain 8325-4 is a well-characterized laboratory
strain that has been used in numerous studies of experimental keratitis
in both rabbit and murine models.14–16,28,29 All S. aureus isolates
(Table 1) were grown at 37°C on tryptic soy agar (TSA, Becton
Dickinson and Co., Sparks, MD) and sub-cultured in tryptic soy broth
(TSB, Becton Dickinson and Co.) at 37°C for 18 hours.
Animals
New Zealand White rabbits (n  4 eyes per group) were obtained from
Harlan Sprague Dawley, Inc. (Indianapolis, IN). All animals were spe-
cific-pathogen free and were maintained according to institutional
guidelines and tenets of the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research.
Before any procedure was performed, each rabbit was anesthetized
as previously described.14–16,37–39
Hemolysis Assays
Freshly collected rabbit erythrocytes were centrifuged to a pellet and
resuspended in 10 mM phosphate-buffered saline (PBS; pH 7.2) with
0.02% gelatin; this washing procedure was repeated three times.
Washed erythrocytes were diluted to a concentration of 108 cells per
mL. Purified -toxin (Sigma-Aldrich, St. Louis, MO) was serially diluted
twofold in microtiter plates, rabbit erythrocytes (107 per well) were
added to the -toxin dilutions, and the plates were incubated at 37°C
until the erythrocytes in the control lacking -toxin had settled. The
highest dilution producing red cell lysis was considered the end point.
One hemolytic unit was equivalent to an -toxin dilution that lysed
erythrocytes but could not cause lysis on further dilution.
For inhibition of hemolysis, supernatants of overnight cultures or
purified -toxin samples were serially diluted twofold in a fashion
similar to that described above for assays performed using -toxin.
Erythrocytes (107 per well) were mixed at 4°C with PBS, 0.1% CD
(Sigma), or 0.1% CD-cholesterol (Sigma) and then added to dilutions of
the culture supernatant or purified toxin in microtiter plates. The
dilutions producing lysis were observed after 30 minutes. All hemolysis
inhibition assays were performed in duplicate or triplicate and were
repeated twice.
Intrastromal Injection of -Toxin
-Toxin (12 hemolytic units) was injected into the stroma of rabbit
corneas (n  4 eyes) to evaluate the subsequent development of
pathologic changes at 7 hours after toxin injection. -Toxin in PBS or
-toxin in 1% CD, or 1% CD-cholesterol was incubated for 30 minutes
at 4°C then injected into rabbit corneas (n  4 per group). The
pathologic changes were observed and the diameter of erosions was
measured at 2, 5, and 7 hours postinjection using fluorescein strips
(Fluorets, Aubenas, France). By 7 hours after injection, the epithelial
erosions in eyes injected with -toxin in PBS reached their maximal
diameter. Heat-inactivated -toxin (n  4 eyes) served as a negative
control.
Experimental Keratitis
Rabbits (n  4 eyes per group) were infected as previously described,
injecting approximately 100 colony forming units (CFU) of strain
8325-4 or strain 60171, a clinical isolate, in 10 L of TSB into the
stroma of the cornea.14,16,37 Accuracy of the inoculum size was verified
by plating aliquots (100 L) of serial dilutions in triplicate on TSA.
Treatment of Keratitis
At 7 hours postinfection (PI), treatment began and consisted of a single
topical drop of PBS, 1% CD, or 1% CD-cholesterol every 15 minutes
from 7 to 8 hours PI. Then, beginning at 8.5 hours PI, a single drop was
administered every 30 minutes until 13 hours PI; a total of 15 drops per
eye. At 13 hours PI, corneal erosions were measured and all eyes
underwent slit lamp examination (SLE) to quantify pathologic changes.
Slit Lamp Examination
SLE of pathologic changes of rabbit eyes was performed by two
masked observers as described previously.14–16,37–39
Colony Forming Unit Determination
Corneas of rabbits infected with either S. aureus 8325-4 or 60171 were
harvested at 14 hours PI and bacteria were quantified as described
previously.14–16,37–39
Statistics
Statistical analyses were performed using statistical analysis software
(SAS [Cary, NC] or Microsoft Excel [Seattle, WA]) as previously de-
scribed.14–16,28,29,37–39
RESULTS
In Vitro Inhibition of -Toxin
To test whether CD or CD-cholesterol could inhibit the action
of -toxin, aliquots of erythrocytes were mixed with PBS, 0.1%
CD, or 0.1% CD-cholesterol and then added to serial dilutions
of purified -toxin. The -toxin titer for the sample in PBS was
approximately 4096 (Fig. 1A). The -toxin titer for the mixture
with CD was reduced only twofold compared with the mixture
with only PBS (Fig. 1B). In contrast, the hemolysis titer of the
same amount of -toxin incubated with CD-cholesterol was
approximately 4 (Fig. 1C), a reduction in titer of 500-fold.
A higher concentration of -toxin was tested for inhibition
using 0.1% CD-cholesterol. The hemolytic titer of the -toxin in
PBS was 65,536 (Fig. 1D), but when the -toxin preparation
was incubated with CD-cholesterol the titer was reduced to 4,
approximately a 16,000-fold decrease in hemolytic activity.
The ability of CD-cholesterol to inhibit the hemolytic activ-
ity of -toxin in culture supernatants of multiple S. aureus
strains was then tested. Rabbit erythrocytes incubated with
CD-cholesterol or PBS were added to serially diluted culture
supernatants of six S. aureus strains. For all six strains tested,
at least a fourfold inhibition of hemolytic activity was observed
(Table 1).
In Vivo Inhibition of -Toxin
Because CD-cholesterol inhibits hemolysis of rabbit erythro-
cytes by -toxin, there was interest in determining if this
inhibitor could limit -toxin effects on the rabbit cornea.
-Toxin (12 hemolytic units) was incubated with PBS, 1% CD,
or 1% CD-cholesterol for 30 minutes at 4°C. After incubation,









8325-4† 2048 0 2048
70490‡ 32 8 4
60171‡ 128 4 32
30084‡ 16 0 16
30281‡ 64 16 4
30155‡ 128 16 8
* Residual hemolysis can, to a limited degree, be mediated by a
hemolysin other than alpha-toxin (e.g., gamma-toxin).
† Gift from Timothy Foster, University of Dublin, Dublin, Ireland.
‡ Gift from David Stroman, Alcon Laboratories, Fort Worth, TX.
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each mixture was injected intrastromally into rabbit corneas
and the size of epithelial erosion was measured at 2, 5, and 7
hours, the latter being the time of maximal erosion diameter
(Fig. 2).
The corneal erosion sizes at all times studied for the eyes
receiving toxin mixed with CD-cholesterol were significantly
smaller than that of eyes receiving toxin mixed with PBS (P 
0.0165; Table 2).
The erosion sizes of eyes injected with toxin mixed with CD
alone were significantly smaller than that of eyes injected with
toxin mixed with PBS at 2 hours postinjection (P  0.0131),
but not at 5 or 7 hours postinjection (P  0.1977).
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FIGURE 1. In vitro analysis of -toxin inhibition with 0.1% CD-cholesterol, or 0.1% CD. Rabbit erythrocytes (108 per mL) were either incubated
with 0.1% CD-cholesterol, 0.1% CD, or untreated for 30 minutes at 4°C. Serial dilutions (1:2) of -toxin were made in microtiter plates. Aliquots
of erythrocytes were added to each well (107 per well). Untreated erythrocytes were suspended in PBS with 0.02% gelatin to serve as a negative
control. (A) Untreated erythrocytes were incubated with -toxin. The hemolytic titer of the -toxin was 4096. (B) Erythrocytes treated with 0.1%
CD did not demonstrate a significant reduction in -toxin titer compared with the negative control, a two-fold reduction. (C) The hemolytic titer
of -toxin was reduced from 4096 to 4 when the red blood cells were incubated with 0.1% CD-cholesterol, a reduction of approximately 500-fold.
(D) Erythrocytes were incubated with -toxin at an increased concentration. The hemolytic titer was 65,536. (E) Erythrocytes were incubated with
0.1% CD-cholesterol, but with an increased concentration of -toxin. The hemolytic titer was reduced from 65,536 to 4, a reduction of
approximately 16,000.
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The corneal erosion sizes of eyes injected with toxin mixed
with CD-cholesterol were significantly smaller than that of eyes
injected with toxin mixed with CD alone at 7 hours postinjec-
tion (P  0.0048), but not at 2 or 5 hours postinjection (P 
0.1173).
In Vivo Treatment of S. aureus Keratitis
The studies described above demonstrate that the lytic effects
of -toxin on erythrocytes and the effects of purified toxin on
rabbit corneas can be inhibited by CD-cholesterol. These find-
ings raised the possibility that CD-cholesterol could treat cor-
neas infected with S. aureus. Rabbit corneas were injected
with either S. aureus strain 8325-4 or S. aureus clinical isolate
60171. Rabbit eyes were treated from 7 to 13 hours PI with
PBS, 1% CD, or 1% CD-cholesterol. At 13 hours PI, the rabbits
were observed for pathologic changes, and erosion formation
(Fig. 2B). At 14 hours PI, the rabbits were euthanatized and the
corneal tissue was harvested to determine the number of bac-
teria present.
At 13 hours PI, S. aureus strain 8325-4 infected eyes were
evaluated by SLE to quantify pathologic changes (Fig. 3). Eyes
treated with PBS had an average SLE score of 9.94  0.37 (Fig.
4A). The eyes treated with CD had an average SLE score of
9.23  0.39, which was statistically similar to the PBS treated
eyes (P  0.2191). In contrast, eyes treated with CD-choles-
terol had a significantly lower SLE score of 6.35  0.28 (P 
0.0001). The SLE score of the rabbits treated with CD-choles-
terol was significantly lower than the SLE score of the eyes
treated with CD (P  0.0002).
At 13 hours PI, eyes infected with S. aureus strain 8325-4
and treated with PBS developed erosions of 5.89  0.36 mm
in diameter (Fig. 4B). Eyes treated with CD had corneal
erosions of 4.55  0.28 mm, a size significantly smaller than
that of eyes treated with PBS (P  0.0103). Eyes treated with
CD-cholesterol had corneal erosions measuring 4.25  0.20
mm in diameter, a size also significantly smaller than the
PBS-treated eyes (5.89  0.36; P  0.0017). The eyes treated
with CD-cholesterol or CD had similar erosion sizes (P 
0.4002).
The number of surviving S. aureus 8325-4 was determined
at 14 hours PI. The PBS treated eyes had 1.12  107  3.66 
106 bacteria per cornea. The eyes treated with CD-cholesterol
or CD had 5.04  106  1.56  106 or 9.36  106  4.22 
105 bacteria per cornea, respectively, which was not signifi-
cantly different from the number of bacteria per cornea in the
eyes treated with PBS (P  0.1941). The eyes treated with
CD-cholesterol and CD had statistically similar numbers of
bacteria (P  0.0648).
Strain 60171, an ocular clinical isolate, was injected into the
corneas of rabbits to determine the effectiveness of treatments
with CD-cholesterol, CD, or PBS (Fig. 3). As described above,
the pathologic changes and erosion development were ob-
served via SLE at 13 hours PI (Fig. 2B) whereas the number of
surviving bacteria was determined at 14 hours PI.
FIGURE 2. Photographs of rabbit
corneas injected with -toxin. Rabbit
corneas (n  4 corneas per group)
were injected with 12 hemolytic
units of -toxin suspended in 1% CD-
cholesterol, 1% CD, or PBS. At 2, 5,
and 7 hours postinjection, erosions
were stained with fluorescein and
measured. Eyes injected with -toxin
suspended in CD-cholesterol had
smaller erosions compared with
-toxin–injected eyes. CD afforded
some protection from large erosion
formation for a short time, but by 5
hours postinjection the CD failed to
protect the cornea and the erosion
formation was similar to the erosions
diameters of the eyes injected with
-toxin mixed with PBS.
TABLE 2: Erosion Diameters of Rabbit Injected with Alpha-Toxin Mixed with 1% CD-Cholesterol, 1% CD, or PBS
Time
Postinjection






vs. PBS CD vs. PBS
2 hours 1.75  1.03 2.40  1.22 6.20  0.35 0.6925 0.0165 0.0131
5 hours 3.00  0.71 5.30  1.16 7.05  0.50 0.1173 0.0028 0.1977
7 hours 3.88  0.66 8.10  0.23 7.64  0.33 0.0048 0.0041 0.2984
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Eyes treated with PBS had an average SLE score of 9.38 
0.53 (Fig. 5A). The eyes treated with CD had an average SLE
score of 9.02  0.90, a score which was statistically similar to
the eyes treated with PBS (P  0.7403). In contrast, eyes
treated with CD-cholesterol had reduced pathology compared
with PBS treated eyes; the average SLE score of CD-cholesterol
treated eyes was 4.83  0.30, a value which was significantly
lower than the eyes treated with PBS (P  0.0001). Further-
more, the eyes treated with CD-cholesterol had statistically
lower average SLE scores than the eyes treated with CD (P 
0.0013).
The diameter of corneal epithelial erosions of eyes infected
with 60171 and treated with PBS was 5.33  0.21 mm (Fig.
FIGURE 3. Photographs of rabbit
corneas infected with S. aureus ker-
atitis treated with 1% CD-cholesterol,
1% CD, or PBS. Rabbit corneas were
injected with 102 CFU of S. aureus
8325-4 or 60171. Treatments began
at 7 hours PI until 13 hours PI. A
single topical drop was applied every
15 minutes between 7 and 8 hours
PI. Starting at 8.5 hours, drops were
applied every 30 minutes until 13
hours PI. At 13 hours PI, all eyes
underwent SLE scoring and photo-
graphs were taken to record the de-
gree of pathologic change.
FIGURE 4. Effect of CD-cholesterol treatment of eyes infected with
strain 8325-4. Rabbit corneas were injected with 102 CFU of S. aureus
8325-4. Eyes were randomized and treated with 1% CD-cholesterol, 1%
CD, or PBS from 7 to 13 hours PI. At 7 hours PI, eyes were treated with
a single topical drop every 15 minutes from 7 to 8 hours PI. At 8.5 hours
PI, eyes were treated with a single topical drop every 30 minutes until 13
hours PI (a total of 15 drops). At 13 hours PI, the eyes were evaluated by
SLE (A) and erosion diameters were measured using fluorescein strips (B).
The pathologic changes were observed then averaged and statistical com-
parisons were performed using one-way ANOVA. The erosions were
averaged and statistical comparisons using analysis of variance and Stu-
dent’s t-test were performed. Error bars are the SEM. P  0.05, for either
test, was considered significant. (A) Eyes treated with CD-cholesterol had
a significantly lower SLE score than either the eyes treated with 1% CD or
with PBS (P  0.0002 and P  0.0001, respectively). The eyes treated
with 1% CD or with PBS had statistically similar SLE scores (P  0.2191).
(B) The eyes treated with 1% CD-cholesterol or 1% CD had significantly
smaller erosions than the PBS treated eyes (P  0.0017 and P  0.0103,
respectively). The eyes treated with 1% CD-cholesterol or 1% CD had
erosion diameters similar to one another (P  0.4002).
FIGURE 5. Effect of CD-cholesterol treatment of eyes infected with
strain 60171. Eyes were treated and evaluated as described for Figure
3. Error bars are the SEM. (A) Eyes treated with CD-cholesterol had
significantly lower SLE scores than either the eyes treated with 1% CD
or PBS (P  0.0013, or P  0.0001, respectively). In contrast, the
CD-treated eyes had similar SLE scores compared to the PBS-treated
eyes (P  0.7403). (B) The eyes treated with 1% CD-cholesterol had
significantly smaller erosions than either the eyes treated with 1% CD
alone or the eyes treated with PBS (P  0.0220 and P  0.0003,
respectively). There was no statistical difference between the eyes
treated with 1% CD and the eyes treated with PBS (P  0.2131).
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5B). The diameter of corneal erosions in eyes treated with CD
was 4.83  0.31 mm, a size statistically similar to eyes treated
with PBS (P  0.2131). In contrast, eyes treated with CD-
cholesterol had significantly smaller corneal erosions measur-
ing 3.83  0.17 mm than either the PBS-treated or CD-treated
eyes (P  0.0003 or P  0.0220, respectively).
At 14 hours PI, the corneas were harvested to obtain the
number of CFU present in the corneas. There were 1.48  107
 2.55  106 bacteria in the corneas of the eyes treated with
PBS. In the eyes treated with CD, there were 2.42  107 
8.96  106 bacteria, which is not significantly different from
the eyes treated with PBS (P  0.4687). There were 8.78  106
 1.61  106 bacteria found in eyes treated with CD-choles-
terol, which was similar to the numbers of bacteria found in
the eyes treated with CD or with PBS (P  0.1017).
DISCUSSION
The present study demonstrates that CD-cholesterol is an ef-
fective inhibitor of -toxin that can block the lytic action on
erythrocytes and, more importantly, protect the cornea and
surrounding tissues from toxin action during infection or when
toxin is injected into the cornea. CD-cholesterol limited toxin
action on infected eyes, but did not reduce bacterial growth or
kill infecting bacteria. This implies that CD-cholesterol inhibi-
tion of -toxin achieved an effective therapy of the infected
eyes despite the continued growth of bacteria and the continu-
ing production of -toxin. CD-cholesterol inhibition of -toxin
was not strain specific; that is, the inhibitor was active for
commercial toxin as well as toxin produced by a variety of
strains, including ocular clinical isolates (Table 1).
The mechanism by which CD-cholesterol inhibits -toxin
has not yet been demonstrated. The effectiveness of choles-
terol as an inhibitor of the toxin is not unexpected, because
Raff et al.31 previously demonstrated that -toxin activity was
weakly inhibited by a high concentration of hydrocortisone or
methylprednisolone. It has been determined that caveolin, as
found in lipid rafts, is an important glucocorticosteroid recep-
tor that could bind molecules like methylprednisolone, hydro-
cortisone, or, in the present study, cholesterol.40 Pany et al.32
and Vijayvargia et al.33,35 have demonstrated that -toxin ac-
tivity is dependent on caveolin-1. Vijayvargia et al.35 have also
demonstrated that -toxin activity on cells can be delayed by
sequestering cholesterol, or inhibited altogether when choles-
terol is depleted from cells. Therefore, a possible mechanism
for the effectiveness of CD-cholesterol as an inhibitor of
-toxin could be that CD-cholesterol competes for the same
cellular target as -toxin. This competitive binding to the
cellular target molecule would reduce the number of caveolin
molecules available to -toxin resulting in fewer cells being
lysed as a consequence of -toxin pore formation.
There have also been reports of -toxin inhibition by mod-
ified CD.36 Karginov et al.36 showed that hepta-6–substituted
CD molecules can create a molecule that interferes with the
lytic action of the toxin. These modified CD molecules are
thought to have affinity for the -toxin heptamer. Specifically,
the modified CD molecules are thought to occlude the central
pore of the toxin. Relative to the present study, one could
speculate that the cholesterol molecule in CD-cholesterol in-
teracts with the central portion of the -toxin pore. Thus, the
cholesterol in complex with CD is envisioned to occlude the
toxin pore in a manner similar to modified-CD inhibitors of
-toxin described by Karginov et al.36
The CD molecule alone had variable effects on the action of
-toxin. In the in vitro hemolysis assay, CD alone failed to
significantly inhibit the hemolytic action of -toxin. In con-
trast, when CD was mixed with -toxin then injected into
rabbit corneas, there were some protective effects mediated by
CD; that is, at 2 hours postinjection the corneas showed stain-
ing with fluorescein, but the epithelium was still intact. The
fluorescein had penetrated under the epithelial layer suggest-
ing that the layer had been partially loosened by the toxin.
However, at 5 hours postinjection, the eyes developed ero-
sions comparable to eyes injected with toxin mixed with PBS.
Furthermore, the application of CD alone to eyes infected with
S. aureus 8325-4 reduced the size of corneal erosions, but CD
alone did not reduce the overall SLE score. These findings can
be understood if one considers that, in the eye, the CD mole-
cule can react with cholesterol or other lipid present in the tear
film or surrounding tissues to form a complex that has signif-
icant inhibitory action on -toxin. Because of the greater avail-
ability of lipids in the eye (e.g., tear film) than in the erythro-
cyte lysis assay, such spontaneous formation of an inhibitory
complex could be more likely to occur in vivo than in the
erythrocyte suspension used for the hemolysis assays in vitro.
-Toxin, as has been demonstrated by virulence studies of
bacterial mutants in rabbits and mice, can cause the majority of
the pathologic changes observed during ocular infec-
tion.14–16,28,29 Studies with purified -toxin injected into rab-
bit corneas show that nanogram quantities of -toxin are tox-
ic.16 -Toxin is produced in readily detectable quantities by
most isolates. Strain Newman was reportedly deficient in
-toxin production, but more recent studies showed that the
very small amount of -toxin produced by this strain made a
significant contribution to its virulence in the rabbit cor-
nea.37,38 Additional findings on the importance of -toxin to
corneal virulence have been obtained through the study of
-toxin neutralizing antibody.39 Neutralizing antibody was ca-
pable of inhibiting the damage associated with -toxin during
keratitis infection without affecting the growth of bacteria.
Although these studies were performed in a rabbit model of
keratitis, the action of -toxin on human cells is very similar to
its action on rabbit cells indicating that the results could be
relevant to humans.
Based on the demonstrated importance of -toxin to kera-
titis, the treatment of Staphylococcus keratitis with an inhibitor
of -toxin could be a valuable adjunctive therapy that could
potentially limit corneal damage while an antibiotic therapy
kills the infecting bacteria. The inhibition of -toxin activity
could be especially beneficial in those cases in which the
antibiotic therapy is slow or ineffective at killing the infecting
bacteria in the cornea.
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